GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (FRA:CPH) » Definitions » Net Income Including Noncontrolling Interests

Histogen (FRA:CPH) Net Income Including Noncontrolling Interests : €-11.58 Mil (TTM As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Histogen Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Histogen's Net Income Including Noncontrolling Interests for the three months ended in Sep. 2023 was €-3.61 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2023 was €-11.58 Mil.

Histogen Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Histogen's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Net Income Including Noncontrolling Interests Chart

Histogen Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Income Including Noncontrolling Interests
-2.70 -15.47 -13.28 -10.05

Histogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.64 -2.80 -3.24 -1.93 -3.61

Histogen Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-11.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Histogen Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Histogen's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Histogen (FRA:CPH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (FRA:CPH) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
GLMD BLCM NBY CYTO RUBY AGTX CFRX ADTX NTRR ISCO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
HSTO:USA
Address
10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
Website
https://www.histogen.com
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Histogen (FRA:CPH) Headlines

No Headlines